Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice

Metabolism: Clinical and Experimental

Volumn 57, Issue 5, 2008, Pages 691-697

  Matsumoto, Masakazu ^a   Tanimoto, Mitsuo ^a   Gohda, Tomohito ^a   Aoki, Tatsuya ^a   Murakoshi, Maki ^a   Yamada, Kaori ^a   Yamazaki, Takahiko ^a   Kaneko, Shigeru ^a   Horikoshi, Satoshi ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOSYLATED HEMOGLOBIN; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; PITAVASTATIN; PROTEIN P47; RNA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIET RESTRICTION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MICROALBUMINURIA; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GTP CYCLOHYDROLASE; HEMOGLOBIN A, GLYCOSYLATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN KINASE C; QUINOLINES; RNA, MESSENGER; TYROSINE;

EID: 42949130547     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.01.007     Document Type: Article

References (31)

1. Epstein M., and Campese M. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis 45 (2005) 2-14
2. McFarlane S.I., Muniyappa R., Francisco R., and Sowers J.R. Pleiotropic effects of statins: lipid reduction and beyond. J Chem Endocrinol Metab 87 (2002) 1451-1458 [Review]
3. Endres M., and Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 35 (2004) 2708-2711
4. Usui H., Shikata K., Matsuda M., Okada S., Ogawa D., Yamashita T., et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18 (2003) 265-272
5. Ota T., Takamura T., Ando H., Nohara E., Yamashita H., and Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46 (2003) 843-851
6. Zhu B., Shen H., Zhou J., Lin F., and Fu Y. Effects of simvastatin on oxidative stress in streptozocin-induced diabetic rats. Nephron Exp Nephrol 101 (2005) e1-e8
7. Onozato M.L., Tojo A., Goto A., Fujita T., and Wilcox C.S. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 61 (2002) 186-194
8. Tsubouchi H., Inoguchi T., Sonta T., Sato N., Sekigichi N., et al. Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 39 (2005) 444-452
9. Danesh F.R., Sadeghi M.M., Amro N., Phillips C., Zeng L., Lin S., et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci U S A 99 (2002) 8301-8305
10. Prabhakar D.S. Role of nitric oxide in diabetic nephropathy. Semin Nephrol 24 (2004) 333-344 [Review]
11. Herrera M., and Garvin L. Recent advances in the regulation of nitric oxide in the kidney. Hypertension 45 (2005) 1062-1067 [Review]
12. Satoh M., Fujimoto S., Haruna Y., Arakawa S., Horike H., Komai N., et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288 (2005) 1144-1152
13. Hattori Y., Nakanishi N., Akimoto K., Yoshida M., and Kasai K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase 1 mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 176-182
14. Shinozaki K., Nishiop Y., Okamura T., Yoshida Y., Maegawa H., Kojima H., et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res (2000) 566-573
15. Bevers L.M., Braam B., Post J.A., Zonneveld A., Rabelink J., Koomans H.A., et al. Tetrahydrobiopterin, but not l-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension 47 (2006) 87-94
16. Etoh T., Inoguchi T., Kakimoto M., Sonoda N., Kobayashi K., Kuroda J., et al. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22 Phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 46 (2003) 1428-1437
17. Kitada M., Koya D., Sugimoto T., Isono M., Araki S., Kashiwagi A., et al. Translocation of glomerular p47 phox and p67 phox by protein kinase C-b activation is required for oxidative stress in diabetic nephropathy. Diabetes 52 (2003) 2603-2614
18. Nishimura M. Breeding of mice strains for diabetes mellitus. Exp Anim 18 (1969) 147-157
19. Okazaki M., Saito Y., Udaka Y., et al. Diabetic nephropathy in KK and KK-Ay mice. Exp Anim 51 (2002) 191-196
20. Fan Q., Liao J., Kobayashi M., Yamashita M., Gu L., Gohda T., et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 19 (2004) 3012-3020
21. y/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology 11 (2006) 29-35
22. Wasselman S., Laufs U., Muller K., Konkol C., Ahlbory K., Baumer T., et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22 (2002) 300-305
23. Danesh F.R., and Kanwar Y.S. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 18 (2004) 805-815 [Review]
24. Holstein S.A., Christine L., Wolford-Lenane C.L., and Hohl R.J. Consequences of mevalonate depletion. J Biol Chem 277 (2002) 10678-10682
25. y/Ta mice. Metabolism 56 (2007) 160-167
26. Booth A.A., Khalifah R.G., Todd P., and Hudson B.G. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 272 (1997) 5430-5437
27. Miyoshi H., Taguchi T., Sugiura M., Takeuchi M., Yanagisawa K., Watanabe Y., et al. Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. Horm Metab Res 34 (2002) 371-377
28. Asaba K., Tojo A., Onozato M.L., Goto A., Quinn M.T., Fujita T., et al. Effects of NDPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67 (2005) 1890-1898
29. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Leefer D.J., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
30. Wong V., Stavar L., Szeto L., Uffelman K., Wang C.H., Fantus I.G., et al. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 184 (2006) 348-355 [Review]
31. Svesson M., and Eriksson J.W. Insulin resistance in diabetic nephropathy-cause or consequence?. Metabolism 22 (2006) 401-410